| Summary: | Lung cancer is the most common human malignancy worldwide and can be divided
into different types of carcinomas depending on their pathological features.
Advances in medical science and technology have led to the identification of some
lung cancer-related marker genes, including
EGFR (epidermal growth factor receptor), BRAF
(B-Raf proto-oncogene), RAS (RAS proto-oncogene, GTPase) and HER2 (human
epidermal growth factor receptor 2). However, the underlying biomarker and key
genes associated with different types of lung cancer are still poorly understood.
In this study, we analyzed a GEO (Gene Expression Omnibus) dataset and identified
28 upregulated intersection DEGs (different expression genes) and 125
downregulated intersection DEGs among AC (adenocarcinoma), PTC (primary typical
carcinoid), PLCC (primary large cell carcinoma), PLCNC (primary large cell lung
carcinoma) and PSCLC (primary small cell lung carcinoma). Through PPI
(protein-protein interaction) network analysis, we identified 14 genes among the
DEGs, namely MFAP4 (microfibril-associated protein 4), PDZD2 (PDZ domain
containing 2), FBLN1 (fibulin 1), FBLN5 (fibulin 5), EFEMP1 (EGF containing
fibulin extracellular matrix protein 1), KDR (kinase insert domain receptor),
S1PR1 (sphingosine-1-phosphate receptor 1), CAV1 (caveolin 1), GRK5 (G
protein-coupled receptor kinase 5), EDNRA (endothelin receptor type A), EDNRB
(endothelin receptor type B), CALCRL (calcitonin receptor-like receptor), PTGER4
(prostaglandin E receptor 4), and ADRB1 (adrenoceptor beta 1), which were found
to be downregulated in different subtypes of lung cancer and associated with poor
survival outcomes. In addition, most of the screened DEGs demonstrated good
predictive ability in LUAD (lung adenocarcinoma) and LUSC (lung squamous cell
carcinoma). Among them, MFAP4 was found to promote cell proliferation while also
suppressing cell migration and angiogenesis. In summary, we propose MFAP4, PDZD2,
FBLN1, FBLN5, EFEMP1, KDR, S1PR1, CAV1, GRK5, EDNRA, EDNRB, CALCRL, PTGER4 and
ADRB1 as potential prognostic markers in lung cancer patients.
|
|---|